Antiplatelet Prophylaxis Reduces the Risk of Early Hepatic Artery Thrombosis Following Liver Transplantation in High-Risk Patients

Transpl Int. 2024 Dec 18:37:13440. doi: 10.3389/ti.2024.13440. eCollection 2024.

Abstract

The prevention of hepatic artery thrombosis (HAT) is pivotal for graft survival immediately after liver transplantation (LT). This study aimed to identify risk factors (RF) for early HAT (eHAT) and assess the benefit of antiplatelet prophylaxis (AP). This retrospective single-center study included 836 adult patients who underwent LT between 2007 and 2022. AP was administered for 3 months in N = 127 patients for surgical reasons. In total, 836 patients underwent LT, of whom 5.5% developed eHAT. In multivariable analysis, arterial anastomotic redo (aHR = 4.33), arterial reconstruction (aHR = 3.72) and cryptogenic liver cirrhosis (aHR = 4.25) were independent RFs for eHAT and AP appeared to be protective (aHR = 0.18). Indeed, in patients with at least one RF who received AP (RF+AP+, n = 94), the eHAT rate was significantly lower (3.2% vs. 21.3%, p < 0.001) than in those with RF who did not receive AP (RF+AP-, n = 89). The effect was even more pronounced when focusing on surgical RF alone (i.e., redo and/or reconstruction) with an additional improvement in 1 year graft survival of 85.3% vs. 70.4%, p = 0.02. AP did not pose an increased risk of bleeding. In conclusion, the main RFs for eHAT include arterial anastomotic redo, arterial reconstruction and cryptogenic liver cirrhosis as LT indications. Our results suggest that AP may protect against eHAT development in these high-risk patients.

Keywords: 1-year graft survival; antiplatelet prophylaxis; hepatic artery thrombosis; liver transplantation; risk factors.

MeSH terms

  • Adult
  • Aged
  • Female
  • Graft Survival*
  • Hepatic Artery*
  • Humans
  • Liver Cirrhosis / complications
  • Liver Cirrhosis / surgery
  • Liver Transplantation* / adverse effects
  • Male
  • Middle Aged
  • Platelet Aggregation Inhibitors* / therapeutic use
  • Postoperative Complications / etiology
  • Postoperative Complications / prevention & control
  • Retrospective Studies
  • Risk Factors
  • Thrombosis* / etiology
  • Thrombosis* / prevention & control

Substances

  • Platelet Aggregation Inhibitors

Grants and funding

The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. IM is a recipient of the ELITE grant (PN-III-P4-IDPCE2020-1091) by the Romanian Executive Agency for Higher Education, Research, Development and Innovation Funding.